Reader Comments
Post a new comment on this article
Post Your Discussion Comment
Please follow our guidelines for comments and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:
- Remarks that could be interpreted as allegations of misconduct
- Unsupported assertions or statements
- Inflammatory or insulting language
Thank You!
Thank you for taking the time to flag this posting; we review flagged postings on a regular basis.
closeMedia Coverage of This Article
Posted by PLOS_ONE_Group on 26 Oct 2012 at 22:48 GMT
The following article represents some of the media coverage that has occurred for this paper:
Publication: Reuters
Title: “Phase III PAH outcome study with macitentan (Opsumit) presented at CHEST - Significant reduction in the risk of morbidity and mortality | Reuters”
http://www.reuters.com/ar...
Publication: Reuters
Title: “Actelion submits a New Drug Application to the FDA for macitentan (Opsumit) for the treatment of patients with pulmonary arterial hypertension | Reuters”
http://www.reuters.com/ar...
If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.
RE: Media Coverage of This Article
PLOS_ONE_Group replied to PLOS_ONE_Group on 30 Nov 2012 at 23:13 GMT
The following article represents some of the media coverage that has occurred for this paper:
Publication: Reuters
Title: “Actelion submits the registration dossier for macitentan (Opsumit) to the European Medicines Agency (EMA) | Reuters”
http://www.reuters.com/ar...
If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.
RE: RE: Media Coverage of This Article
PLOS_ONE_Group replied to PLOS_ONE_Group on 17 May 2013 at 22:23 GMT
The following article represents some of the media coverage that has occurred for this paper:
Publication: Acetlion
Title: “Additional macitentan (Opsumit) data in pulmonary arterial hypertension presented at ATS”
http://www1.actelion.com/...
If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.
RE: Media Coverage of This Article
PLOS_ONE_Group replied to PLOS_ONE_Group on 24 May 2013 at 21:51 GMT
Publication: Pipeline Review
Title: “Additional macitentan (Opsumit) data in pulmonary arterial hypertension presented at ATS | Small Molecules | News Channels”
http://www.pipelinereview...
Media Coverage of This Article
PLOS_ONE_Group replied to PLOS_ONE_Group on 03 Sep 2013 at 22:59 GMT
The following article represents some of the media coverage that has occurred for this paper:
Publication: CNW
Title: “ACTELION | The New England Journal of Medicine Publishes Macitentan Morbidity and Mortality Study in Pulmonary Arterial Hypertension”
http://www.newswire.ca/en...
Publication: IT News
Title: “New macitentan (Opsumit) efficacy data in pulmonary arterial hypertension from SERAPHIN study presented at European Society of Cardiology Congress 2013”
http://www.itnews.it/news...
Publication: The Wall Street Journal
Title: “Further macitentan (Opsumit) data in pulmonary arterial hypertension presented at key congresses - MarketWatch”
http://www.marketwatch.co...
If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.
Media Coverage of This Article
PLOS_ONE_Group replied to PLOS_ONE_Group on 17 Sep 2013 at 15:58 GMT
The following articles represent some of the media coverage that has occurred for this paper:
Publication: 4 Traders
Title: “Actelion Ltd : Macitentan (Opsumit) morbidity and mortality data in pulmonary arterial hypertension from SERAPHIN study presented at European Respiratory Society Congress 2013. | 4-Traders”
http://www.4-traders.com/...
Publication: IT News
Title: “Macitentan (Opsumit) morbidity and mortality data in pulmonary arterial hypertension from SERAPHIN study presented at European Respiratory Society Congress 2013.”
http://www.itnews.it/news...
If you see any additional coverage of this paper in the press or blogosphere, please reply to this thread and add the link to the article.